APM
SGTX

Avidity Partners Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Avidity Partners Management’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-65,459
Closed -$19M – 141
2021
Q1 		$19M Buy
65,459
+12,536
+24% +$4.98M 0.53% 61
2020
Q4 		$33M Buy
+52,923
New +$24M 1.07% 35

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Avidity Partners Management's SGTX Position: Q2 2021 in Review

Avidity Partners Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2021, closing a stake of 65,459 shares — an estimated $19M sold.

Avidity Partners Management first reported a position in SGTX in Q4 2020 and held it in 2 quarters. The position peaked at $33M in Q4 2020. 52 funds tracked by Wall St. Rank hold SGTX as of Q2 2021.

  • Avidity Partners Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Avidity Partners Management sold 65,459 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $19M.
  • Avidity Partners Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Avidity Partners Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $33M in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.